Drug Trial Radar · NCT05699239
A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
326
Actual
Start
Feb 8, 2023
Primary completion
Dec 26, 2023
Study completion Dec 26, 2023
Sponsor
- Lead sponsor
- Taisho Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis
Conditions
- Hyperphosphatemia Patients on Hemodialysis
Interventions
TS-172 10mg bidDrug
oral administration of TS-172 10 mg bid
TS-172 30mg bidDrug
oral administration of TS-172 30 mg bid
TS-172 60mg bidDrug
oral administration of TS-172 60 mg bid
TS-172 20mg tidDrug
oral administration of TS-172 20 mg tid
PlaceboDrug
oral administration of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in serum concentration of phosphorusTime frame: Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.